DNA Swine Genetics

dnaswinegenetics.com

DNA Genetics produces the finest genetics to help producers compete and succeed in today’s pork industry. We are a pork producer-owned genetic company, which provides us with a working, real-world knowledge of commercial pork production. Best People. Best Pig. Best Genetic option.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

EVAXION AND PANTHERNA REVEALS PROMISING PRECLINICAL PROOF OF CONCEPT FOR COMBINED TECHNOLOGIES

Evaxion | February 10, 2023

news image

Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion&#...

Read More

HOW THE CANNABINOID INDUSTRY IS EVOLVING WITH GROWING BIOTECH INFLUENCE

PR Newswire | June 09, 2020

news image

The impending marriage of the biotech industry and the legal (i.e. medical) cannabis industry is looking like it will be a long and happy marriage. As the use of legal marijuana grows globally, the medicinal (as opposed to recreational) revenues will continue to grow and become the dominant share of the legal marijuana market. According to Grand View Research the global legal marijuana market size is expected to reach USD 73.6 billion by 2027. It is anticipated to expand at a CAGR of 18.1% durin...

Read More

Medical

FELIX BIOTECHNOLOGY ANNOUNCES INITIATION OF CYPHY PHASE 1/2 STUDY AT YALE FOR LEAD ASSET

Felix Biotechnology | January 08, 2021

news image

Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and...

Read More

Industrial Impact

IPA’S SUBSIDIARY BIOSTRAND AND BRIACELL ANNOUNCE ARTIFICIAL INTELLIGENCE COLLABORATION AND LICENSE AGREEMENT

BriaCell Therapeutics Corp. | December 01, 2022

news image

IPA an advanced biotherapeutic research and technology company, announced that BioStrand BV an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement with BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. The collaboration will leverage BioStrand’s LENSai™ software, built upon IPA’s proprietary HYFT™ Universal Fingerprint™ technolog...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EVAXION AND PANTHERNA REVEALS PROMISING PRECLINICAL PROOF OF CONCEPT FOR COMBINED TECHNOLOGIES

Evaxion | February 10, 2023

Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion&#...

Read More
news image

HOW THE CANNABINOID INDUSTRY IS EVOLVING WITH GROWING BIOTECH INFLUENCE

PR Newswire | June 09, 2020

The impending marriage of the biotech industry and the legal (i.e. medical) cannabis industry is looking like it will be a long and happy marriage. As the use of legal marijuana grows globally, the medicinal (as opposed to recreational) revenues will continue to grow and become the dominant share of the legal marijuana market. According to Grand View Research the global legal marijuana market size is expected to reach USD 73.6 billion by 2027. It is anticipated to expand at a CAGR of 18.1% durin...

Read More
news image

Medical

FELIX BIOTECHNOLOGY ANNOUNCES INITIATION OF CYPHY PHASE 1/2 STUDY AT YALE FOR LEAD ASSET

Felix Biotechnology | January 08, 2021

Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and...

Read More
news image

Industrial Impact

IPA’S SUBSIDIARY BIOSTRAND AND BRIACELL ANNOUNCE ARTIFICIAL INTELLIGENCE COLLABORATION AND LICENSE AGREEMENT

BriaCell Therapeutics Corp. | December 01, 2022

IPA an advanced biotherapeutic research and technology company, announced that BioStrand BV an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement with BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. The collaboration will leverage BioStrand’s LENSai™ software, built upon IPA’s proprietary HYFT™ Universal Fingerprint™ technolog...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us